18 July, 2013
Headlined by Karen Burg, DL Taylor, Steve Ludbrook and Aaron Morris, CHI’s FAST Congress features three days of innovative presentations for more accurate biological response in drug discovery through novel screening technologies and strategies.
Taking place October 28-30, 2013 in Cambridge, MA, Cambridge Healthtech Institute’s FAST: Functional Analysis and Screening Technologies Congress will deliver both time-tested and novel strategies for refining first-stage drug discovery methods with assay design on three-dimensional tissue models and phenotypic models. The premier event will bring together leading drug research and development teams for the three days of practical discussion, solutions-driven presentations and real-world case studies.
The agenda includes dedicated conferences on Engineering Functional 3-D Tissue Models, Screening and Functional Analysis of 3-D Models, Phenotypic Drug Discovery, and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Additionally, four dinner short courses are available on the topics of Scaffolds: Bridging the Gap between 2-D and 3-D, Automating a 3-D Culture Screening Laboratory, High-Content Phenotypic Screening, and Meeting the Need for Physiologically-Relevant Assays.
Among the full lineup of notable speakers are featured presenters from leading pharmaceutical and academic research teams:
– Karen J.L. Burg, Ph.D., Hunter Endowed Chair and Professor of Bioengineering, Clemson University
– D. Lansing Taylor, Ph.D., Director, University of Pittsburgh Drug Discovery Institute
– Steve Ludbrook, Ph.D., Section Head, Screening and Compound Profiling, GlaxoSmithKline
– Aaron Morris, Ph.D., Lab Head, Cancer Biology, Sanofi Oncology
To view the final agenda, including a full speaker list, program abstracts and registration details, visit http://www.fastcongress.com. Early registration discounts are available until August 2.
Sponsored by: Cambridge Healthtech Institute (CHI)